Dual action of a selective cyclooxygenase-2 inhibitor on vascular endothelial growth factor expression in human hepatocellular carcinoma cells: Novel involvement of discoidin domain receptor 2

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 1, 2012, Pages 73-84

  Lee, Nam Oak ^a   Park, Joong Won ^a   Lee, Jung Ahn ^a   Shim, Ju Hyun ^a   Kong, Sun Young ^a   Kim, Kyung Tae ^a   Lee, Yeon Su ^a  

^a National Cancer Center   (South Korea)

Author keywords

COX 2; DDR2; Hepatocellular carcinoma; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISCOIDIN DOMAIN RECEPTOR 2 GENE; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE SEQUENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; IN VIVO STUDY; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; TUMOR GENE; UPREGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE;

CARCINOMA, HEPATOCELLULAR; CELL GROWTH PROCESSES; CELL HYPOXIA; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; NITROBENZENES; PROMOTER REGIONS, GENETIC; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, MITOGEN; RNA, SMALL INTERFERING; SULFONAMIDES; TRANSFECTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84857049837     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1075-0     Document Type: Article

References (38)

1. Altermann E, Klaenhammer TR (2005) Pathway Voyager: pathway mapping using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. BMC Genomics 6(1): 60. doi: 10.1186/1471-2164-6-60 (Pubitemid 41357675)
2. Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG, Ryu WS (2001) Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 7
3. Baguma-Nibasheka M, Barclay C, Li AW, Geldenhuys L, Porter GA, Blay J, Casson AG, Murphy PR (2007) Selective cyclooxygenase- 2 inhibition suppresses basic Wbroblast growth factor expression in human esophageal adenocarcinoma. Mol Carcinog 46(12): 971-980 (Pubitemid 350234254)
4. Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, Yen SH, Chang FY, Chan WK, Lee SD (2003) Prognostic signiWcance of vascular endothelial growth factor, basic Wbroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 10(4): 355-362 (Pubitemid 40486931)
5. Cheng AS, Chan HL, To KF, Leung WK, Chan KK, Liew CT, Sung JJ (2004) Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int J Oncol 24
6. Gately S (2000) The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 19(1-2): 19-27 (Pubitemid 32004688)
7. Gately S, Li WW (2004) Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 31(2 Suppl 7): 2-11. doi: S0093775404001897 (Pubitemid 38879409)
8. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2(1): 38-47 (Pubitemid 37328806)
9. Hu KQ (2002) Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med 139(4): 234-243. doi: S0022214302336047
10. Iniguez MA, Rodriguez A, Volpert OV, Fresno M, Redondo JM (2003) Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 9(2): 73-78. doi: S1471491402000114 (Pubitemid 36313868)
11. Kern MA, Schoneweiss MM, Sahi D, Bahlo M, Haugg AM, Kasper HU, Dienes HP, Kaferstein H, Breuhahn K, Schirmacher P (2004) Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis 25(7): 1193-1199 (Pubitemid 38968047)
12. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, Nakashima Y, Nakashima O, Kojiro M, Kurohiji T, Sata M (1999) Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dediVerentiation. Hepatology 29(3): 688-696 (Pubitemid 29109581)
13. Kong SY, Park JW, Lee JA, Park JE, Park KW, Hong EK, Kim CM (2007) Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology 46(2): 446-455
14. Levy AP, Levy NS, Wegner S, Goldberg MA (1995) Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 270(22): 13333-13340
15. Li XM, Tang ZY, Zhou G, Lui YK, Ye SL (1998) SigniWcance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 17(1): 13-17 (Pubitemid 28215959)
16. Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, Shibuya M, Makuuchi M, Yazaki Y, Ohnishi S (1997) Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 27(5): 854-861. doi: S0168-8278(97)80323-6
17. Mukhopadhyay D, Datta K (2004) Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin Cancer Biol 14(2): 123-130. doi: 10.1016/j.semcancer.2003.09.019 (Pubitemid 38234754)
18. Park JW, Park JE, Lee JA, Lee CW, Kim CM (2006) Cyclooxygenase- 2 (COX-2) is directly involved but not decisive in proliferation of human hepatocellular carcinoma cells. J Cancer Res Clin Oncol 132(3): 184-192
19. Park HS, Kim KR, Lee HJ, Choi HN, Kim DK, Kim BT, Moon WS (2007) Overexpression of discoidin domain receptor 1 increases the migration and invasion of hepatocellular carcinoma cells in association with matrix metalloproteinase. Oncol Rep 18(6): 1435-1441
20. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2): 74-108. doi: 55/2/74 (Pubitemid 40372904)
21. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4(7): 505-518. doi: 10.1038/nrc1387 (Pubitemid 38868620)
22. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST (2004) Prognostic signiWcance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91(10): 1354-1360 (Pubitemid 39331462)
23. Semela D, Dufour J-F (2005) Vascular endothelial growth factor signaling. In: Dufour JF, Clavien PA (eds) Signaling pathways in liver diseases. Springer, Berlin, pp 91-104
24. Shim JH, Park JW, Kim JH, An M, Kong SY, Nam BH, Choi JI, Kim HB, Lee WJ, Kim CM (2008) Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 99(10): 2037-2044
25. Tang TC, Poon RT, Lau CP, Xie D, Fan ST (2005) Tumor cyclooxygenase- 2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol 11(13): 1896-1902 (Pubitemid 40520983)
26. Tessner TG, Muhale F, Schloemann S, Cohn SM, Morrison A, Stenson WF (2003) Basic Wbroblast growth factor upregulates cyclooxygenase-2 in I407 cells through p38 MAP kinase. Am J Physiol Gastrointest Liver Physiol 284(2): G269-G279 (Pubitemid 36120133)
27. Vogel W, Gish GD, Alves F, Pawson T (1997) The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell 1(1): 13-23. doi: S1097-2765(00)80003-9 (Pubitemid 127376389)
28. Vogel WF, Abdulhussein R, Ford CE (2006) Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signal 18(8): 1108-1116. doi: 10.1016/j.cellsig.2006.02.012 (Pubitemid 43674043)
29. von Marschall Z, Cramer T, Hocker M, Finkenzeller G, Wiedenmann B, Rosewicz S (2001) Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 48(1): 87-96 (Pubitemid 32042647)
30. Wang D, DuBois RN (2004) Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci USA 101(2): 415-416 (Pubitemid 38084650)
31. Wang Y, Sun Y (2002) Insulin-like growth factor receptor-1 as an anticancer target: blocking transformation and inducing apoptosis. Curr Cancer Drug Targets 2(3): 191-207
32. Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inXammation, cancer, and development. Oncogene 18(55): 7908-7916. doi: 10.1038/sj.onc.1203286 (Pubitemid 30066236)
33. Wu T (2006) Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev 32(1): 28-44. doi: 10.1016/j.ctrv.2005.10.004 (Pubitemid 43159775)
34. Wu XZ, Chen D (2006) Cell-matrix talks: eVects on diVerentiation of hepatocellular carcinoma. Minerva Gastroenterol Dietol 52(4): 407-413 (Pubitemid 46166448)
35. Wu XZ, Xie GR, Chen D (2007) Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 22(8): 1178-1182 (Pubitemid 47222667)
36. Xie K, Wei D, Shi Q, Huang S (2004) Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev 15(5): 297-324. doi: 10.1016/j.cytogfr.2004.04.003 (Pubitemid 39140697)
37. Yang JD, Nakamura I, Roberts LR (2011) The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 21(1): 35-43. doi: 10.1016/j.semcancer.2010.10.007
38. Zhao QT, Yue SQ, Cui Z, Wang Q, Cui X, Zhai HH, Zhang LH, Dou KF (2007) Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. Life Sci 80(5): 484-492 (Pubitemid 46019821)